Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC

Share :
Published: 22 Oct 2023
Views: 39
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Choueiri talks to ecancer at ESMO 2023 about the phase II LITESPARK-003 study.

Results he presented indicated that the combination of belzutifan and cabozantinib represents a promising treatment for advanced clear cell renal cell carcinoma.

The study found the treatment option to be effective in both first-line and subsequent-line settings and showed durable anti-tumour activity with a safety profile consistent with prior observations.

These results further support the use of an HIF-2α inhibitor and VEGFR-TKI combination for treating advanced ccRCC.